TABROS PHARMA (PVT). LTD.
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Private pharmaceutical manufacturer · Karachi · Pakistan
Pakistan pharmaceutical manufacturer and marketer with a broad branded portfolio and dedicated pharmacovigilance and product-safety functions.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Tabros Pharma (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- Essa House, 32-1-C, Block-6, P.E.C.H.S., Karachi, Pakistan
- Website
- tabrospharma.com ↗
- Phone
- +92 21 34533416-8
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| DENCITY | Ondansetron | 4 mg/5 mL | Oral solution | 50ml | 127031 | PKR 1,032.55 | PKR 20.65/mL | Near median |
| DENCITY | Ondansetron | 4 MG/2 mL | Injection | 2mlx5's | 127032 | PKR 2,885.81 | PKR 288.58/mL | Near median |
| DENCITY | Ondansetron | 8 mg/4 mL | Injection | 4mlx1's | 127033 | PKR 1,045.64 | PKR 261.41/mL | 7% above median |
| DENCITY | Ondansetron | 8 mg/4 mL | Injection | 4mlx5's | 127033 | PKR 5,228.20 | PKR 261.41/mL | 7% above median |
| DEXASONE | Dexamethasone | 4 mg | Injection | 25x1ml | 010590 | PKR 530.75 | PKR 21.23/mL | 18% above median |
| DEXASONE | Dexamethasone | 4 mg | Injection | 1x5ml | 010590 | PKR 88.06 | PKR 17.61/mL | Near median |
| DIARON | Gliclazide | 80 mg | Tablet | 20's | 019274 | PKR 233.44 | PKR 11.67/tablet | 12% above median |
| Doxycycline | Doxycycline | 100 mg | Capsule | 100's | 012019 | PKR 649.26 | PKR 6.49/capsule | 18% below median |
| Duragab Tablet 10mgRegistry verified | Mirogabalin as Besylate | — | — | — | 137184Official source ↗ | No indexed price | — | — |
| Duragab Tablet 15mgRegistry verified | Mirogabalin as Besylate | — | — | — | 137183Official source ↗ | No indexed price | — | — |
| Duragab Tablet 5mgRegistry verified | Mirogabalin as Besylate | — | — | — | 137185Official source ↗ | No indexed price | — | — |
| E-CLAR | Clarithromycin | 250 mg | Tablet | 10x10's | 019797 | PKR 7,116.34 | PKR 71.16/tablet | 50% above median |
| E-CLAR | Clarithromycin | 250 mg | Tablet | 10'S | 019797 | PKR 741.29 | PKR 74.13/tablet | 56% above median |
| E-CLARSource observed | Clarithromycin | 125 mg | Held for normalizationSource reported: Tablet · structural field conflict | 25ML | 019798Official source ↗ | No indexed price | — | — |
| E-CLARSource observed | Clarithromycin | 125 mg | Held for normalizationSource reported: Tablet · structural field conflict | 60ML | 019798Official source ↗ | No indexed price | — | — |
| E-CLAR | Clarithromycin | 500 mg | Prolonged-release tablet | 5'S | 075990 | PKR 427.48 | PKR 85.50/tablet | 7% below median |
| E-CLARSource observed | Clarithromycin | 250 mg | Held for normalizationSource reported: Tablet · structural field conflict | 60ML | 085613Official source ↗ | No indexed price | — | — |
| E-CLAR DS | Clarithromycin | 500 mg | Tablet | 10'S | 042200 | PKR 939.63 | PKR 93.96/tablet | 12% above median |
| ELZAFLO | Empagliflozin | 10 mg | Tablet | 14's | 116271 | PKR 1,106.88 | PKR 79.06/tablet | Near median |
| ELZAFLO | Empagliflozin | 25 mg | Tablet | 14's | 116272 | PKR 1,324.85 | PKR 94.63/tablet | 6% below median |
| FERRY | Iron polymaltose complex | 50 mg elemental iron/5 mL | Syrup | 120ML | 023821 | PKR 367.57 | PKR 3.06/mL | 28% above median |
| FERRY | Iron polymaltose complex | 50 mg/5 mL | Syrup | 60ML | 023821 | PKR 194.60 | PKR 3.24/mL | 40% above median |
| FERRY | Iron polymaltose complex | 50 mg/5 mL | Syrup | 30ml | 023821 | PKR 55.94 | PKR 1.86/mL | 20% below median |
| FERRY | Iron polymaltose complex | 100 mg | Capsule | 3X10'S | 032015 | PKR 455.88 | PKR 15.20/capsule | 18% above median |
| FERRY | Iron polymaltose complex | 100 mg | Capsule | 1X10'S | 032015 | PKR 129.27 | PKR 12.93/capsule | Near median |
| FERRY-F | Iron polymaltose complex + Folic acid | 100 mg elemental iron + 0.35 mg folic acid | Capsule | 10's | 032982 | PKR 151.32 | PKR 15.13/capsule | 40% above median |
| FERRY-F | Iron polymaltose complex + Folic acid | 100 mg + 0.35 mg | Capsule | 30'S | 032982 | PKR 387.51 | PKR 12.92/capsule | 10% above median |
| FIMRA | Omeprazole | 20 mg | Capsule | 14's | 067217 | PKR 219.74 | PKR 15.70/capsule | 20% below median |
| FIMRA | Omeprazole | 40 mg | Capsule | 14's | 067239 | PKR 461.66 | PKR 32.98/capsule | Near median |
| FIXITIL | Cefixime | 100 mg/5 mL | Suspension | 60ml | 019259 | PKR 553.97 | PKR 9.23/mL | 12% below median |
| FIXITIL | Cefixime | 100 mg/5 mL | Suspension | 30ml | 019259 | PKR 330.35 | PKR 11.01/mL | Near median |
| FIXITIL | Cefixime | 400 mg | Capsule | 5's | 019260 | PKR 548.63 | PKR 109.73/capsule | Near median |
| FIXITIL DS | Cefixime | 200 mg/5 mL | Suspension | 30ml | 042366 | PKR 404.28 | PKR 13.48/mL | Near median |
| FIXITIL DS | Cefixime | 200 mg/5 mL | Suspension | 15ml | 042366 | PKR 146.50 | PKR 9.77/mL | 28% below median |
| FIXITIL-T | Cefixime | 200 mg | Tablet | 5's | 036875 | PKR 227.14 | PKR 45.43/tablet | 30% below median |
| FIXITIL-T | Cefixime | 200 mg | Tablet | 10's | 036875 | PKR 646.37 | PKR 64.64/tablet | Near median |
| FIXITIL-T DS | Cefixime | 400 mg | Tablet | 5's | 083787 | PKR 591.99 | PKR 118.40/tablet | 7% below median |
| FIXITIL-T DS | Cefixime | 400 mg | Tablet | 10's | 083787 | PKR 1,170.97 | PKR 117.10/tablet | 8% below median |
| Flurocort | Fludrocortisone acetate | 0.1 mg | Tablet | 20's | 108902 | PKR 176.59 | PKR 8.83/tablet | Near median |
| Flurocort | Fludrocortisone acetate | 0.1 mg | Tablet | 1's | 108902 | PKR 8.82 | PKR 8.82/tablet | Near median |
| Focin | Fosfomycin disodium | 1 g/vial | Injection | 1 VIAL | 017677 | PKR 550.11 | PKR 550.11/vial/unit | 131% above median |
| Focin | Fosfomycin | 1 G | Injection | 1 VIAL | 017677 | PKR 550.11 | PKR 550.11/vial/unit | 522% above median |
| Focin | Fosfomycin disodium | 1 g/vial | Injection | 1 VIAL | 019256 | PKR 237.85 | PKR 237.85/vial/unit | 57% below median |
| Focin | Fosfomycin | 1 G | Injection | 1 VIAL | 019256 | PKR 237.85 | PKR 237.85/vial/unit | 169% above median |
| Folic Acid | Folic acid | 5 mg | Tablet | 1000 | 010963 | PKR 474.90 | PKR 0.47/tablet | 41% below median |
| Folic Acid | Folic acid | 5 mg | Tablet | 100's | 010963 | PKR 102.63 | PKR 1.03/tablet | 28% above median |
| GAVEL | Ciprofloxacin | 250 MG | Tablet | 10's | 019264 | PKR 367.96 | PKR 36.80/tablet | 44% above median |
| GAVEL | Ciprofloxacin | 500 MG | Tablet | 10's | 019265 | PKR 647.63 | PKR 64.76/tablet | 52% above median |
| GAVELSource observed | Ciprofloxacin | 127.2 mg | IV infusion | 100ml | 019266Official source ↗ | No indexed price | — | — |
| GAVELSource observed | Ciprofloxacin | 127.2 mg | IV infusion | 50ml | 019266Official source ↗ | No indexed price | — | — |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.